Dendritic cell activation via type I interferon pathway

The entry "Dendritic cell activation via type I interferon pathway induction by viral infection of tumor cells" describes a **cellular process** rather than a discrete molecular target. This process involves the **activation and maturation of dendritic cells (DCs)** through the induction of **type I interferons (IFN-I)**—primarily IFN-alpha and IFN-beta—following recognition of viral components in infected tumor cells. Dendritic cells detect viral nucleic acids using pattern recognition receptors such as TLR3, TLR7/8/9, or cytosolic sensors like cGAS/STING. Upon stimulation, DCs produce large amounts of type I IFNs that act in an autocrine and paracrine manner to drive their own phenotypic maturation. Type I IFNs upregulate expression of MHC class II molecules and costimulatory markers (CD80/CD86), enhance antigen processing/presentation capacity, promote migration to lymph nodes via CCR7 upregulation, and facilitate cross-presentation for robust T-cell priming. This mechanism is central both in antiviral immunity and as a component in anti-tumor responses when tumors are infected with viruses or treated with agents that mimic viral infection. However, this is not a single molecule but rather refers to an immunological event involving multiple receptors (e.g., TLRs), cytokines (type I IFNs), transcription factors (IRF7/IRF3), signaling adaptors (MyD88/TRIF), etc. Therefore it does not fit standard definitions for therapeutic targets such as receptor proteins or enzymes.

Other names

Type I interferon-mediated dendritic cell activationIFN-I-induced dendritic cell maturationDC activation by type I IFN

Induction of type I interferon signaling to promote dendritic cell maturation and immune activation